BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for ...

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for ...

Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketonuria (PKU) ...

Jnana said in a statement that the funding will allow it to take JNT-517 through proof-of-concept testing in PKU, a genetic disorder caused by an inability to break down the amino acid phenylalanine ...

BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for ...

Otsuka Pharmaceutical has picked up Boston-based Jnana Therapeutics for $800 million so the Japanese biotech can get its hands on a clinical-stage oral phenylketonuria (PKU) drug. Under the terms of ...

Momentum is building at Jnana Therapeutics Inc. The firm has raised $107 million in a series C round and banked another $50 million up front from a new drug discovery and development pact with Roche ...

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics today announced that Joanne Kotz, Ph.D., a company co-founder, has been named Chief Executive Officer. Dr. Kotz has served as Jnana’s president since ...

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small molecule ...